Patent intelligence · US
US 10406125
Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject
Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 le…
Patent details — US 10406125
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 10, 2019
- Expiration
- Sep 5, 2039
- Applicant
- ADVANCED BIODESIGN
- Claims
- 10
- CPC classes
- A61K, A61K2300/00, A61K31/131, A61K31/136
Quick answer
US 10406125 (Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject) is held by ADVANCED BIODESIGN. Status: granted. Granted Sep 10, 2019. Expires Sep 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ADVANCED BIODESIGN
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2300/00, A61K31/131, A61K31/136, A61K31/137, A61K31/145
More from ADVANCED BIODESIGN
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 10406125?
US 10406125 (Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject) is held by ADVANCED BIODESIGN. Status: granted. Granted Sep 10, 2019. Expires Sep 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10406125?
ADVANCED BIODESIGN is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 10406125 expire?
Our index shows an expiration date of Sep 5, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.